Hoffmann-La Roche Limited
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$96.0M
Doctors Paid
608
Transactions
9,381
2024 Total
$9.1M
Payment Breakdown by Category
Research$94.8M (98.8%)
Consulting$913,272 (1.0%)
Travel$141,778 (0.1%)
Food & Beverage$76,677 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $94.8M | 8,083 | 98.8% |
| Consulting Fee | $913,272 | 273 | 1.0% |
| Travel and Lodging | $141,778 | 316 | 0.1% |
| Food and Beverage | $76,677 | 639 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,343 | 35 | 0.1% |
| Education | $1,300 | 34 | 0.0% |
| Grant | $678.60 | 1 | 0.0% |
Payments by Type
Research
$94.8M
8,083 transactions
General
$1.2M
1,298 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | $18.6M | 0 | 550 |
| ACUTE SCHIZOPHRENIA STUDY | $14.2M | 0 | 418 |
| MORPHEUS BREAST | $3.6M | 0 | 291 |
| AN OPEN LABEL RANDOMIZED MULTICENTER STUDY TO INVESTIGATE PHARMACOKINETICS PHARMACODYNAMICS SAFE | $3.2M | 0 | 300 |
| RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY | $3.1M | 0 | 121 |
| Coated tablet bioequivalence study | $2.9M | 0 | 54 |
| Acute Schizophrenia study | $2.7M | 0 | 143 |
| Morpheus Breast Cancer | $2.4M | 0 | 238 |
| PH IIB OF ASTEGOLIMAB IN COPD | $2.2M | 0 | 413 |
| MORPHEUS CRC | $2.1M | 0 | 144 |
| Morpheus Breast | $1.9M | 0 | 182 |
| MORPHEUS TNBC | $1.9M | 0 | 229 |
| OPERETTA II Ocrelizumab Pediatric Phase III study | $1.8M | 0 | 200 |
| TAAR1 4 FOR NEGATIVE SYMPTOMS | $1.7M | 1 | 336 |
| PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | $1.7M | 0 | 118 |
| BLU667 1101 ARROW ongoing | $1.6M | 0 | 184 |
| A PHASE 1B STUDY EVALUATING THE EFFICACY SAFETY OF ATEZOLIZUMAB AND COTELLIC IN 2L BRAFWT MELANOMA | $1.4M | 0 | 200 |
| Morpheus Melanoma | $1.3M | 0 | 82 |
| ABT 199 GDC 0199 IN 1L DLBCL | $1.3M | 1 | 70 |
| A PHASE IB OPEN LABEL STUDY EVALUATING THE SAFETY TOLERABILITY AND PK OF COBIMETINIB | $1.3M | 0 | 81 |
| A PHASE IB OPEN LABEL STUDY EVALUATING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF COBIMETINIB | $1.3M | 0 | 76 |
| TAAR1 4 for negative symptoms | $1.2M | 1 | 247 |
| PHASE 3 R R CLL WITH GDC0199 BR | $1.1M | 9 | 166 |
| RANDOMIZED DB DD ACTIVE COMPARATOR STUDY OF RITUXIMAB SAFETY EFFICACY IN PEMPHIGUS VULGARIS | $981,357 | 0 | 157 |
| A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis | $840,988 | 1 | 180 |
| STUDY TO ASSESS EFFICACY SAFETY AND TOLERABILITY IN AMBULATORY BOYS WITH DMD | $802,244 | 0 | 75 |
| ASCENDING DOSE STUDY IN BOYS WITH DMD | $755,658 | 0 | 41 |
| RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS | $752,875 | 0 | 66 |
| Efficacy Safety of Obinutuzumab vs MMF in patients with idiopathic nephrotic syndrome | $690,487 | 0 | 132 |
| Double blind study to determine efficacy of ASO Factor B in IgAN | $689,890 | 0 | 154 |
Payments by Medical Specialty
Top Paid Doctors — Page 25
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Dr. Luz Rodriguez, Md, MD | Surgery | Bethesda, MD | $17.67 | $0 |
| Dr. Angeline Nguyen, Md, MD | Ophthalmology | Stanford, CA | $13.91 | $0 |
| Julia Sein, Md, MD | Ophthalmology | Valencia, CA | $13.91 | $0 |
| Angela Zhu, M.d, M.D | Student in an Organized Health Care Education/Training Program | Miami, FL | $13.91 | $0 |
| Karun Arora | Student in an Organized Health Care Education/Training Program | Baltimore, MD | $13.91 | $0 |
| Nora Vera, M.d, M.D | Dermatology | Tampa, FL | $13.79 | $0 |
| Dr. Eugene Ahn, M.d, M.D | Medical Oncology | Chicago, IL | $12.49 | $0 |
| Valerie Suski, Do, DO | Specialist | Pittsburgh, PA | $11.80 | $0 |
About Hoffmann-La Roche Limited
Hoffmann-La Roche Limited has made $96.0M in payments to 608 healthcare providers, recorded across 9,381 transactions in the CMS Open Payments database. In 2024, the company paid $9.1M. The top product by payment volume is Actemra ($23.7M).
Payments were distributed across 52 medical specialties. The top specialty by payment amount is Hematology & Oncology ($604,401 to 31 doctors).
Payment categories include: Food & Beverage ($76,677), Consulting ($913,272), Research ($94.8M), Travel & Lodging ($141,778).
Hoffmann-La Roche Limited is associated with 2 products in the CMS Open Payments database.